Bellast Ultra L Dermal Filler
Cross-linked Hyaluronic Acid 20mg/ml with 0.3% Lidocaine
Bellast Ultra L is a premium dermal filler containing 20mg/ml cross-linked hyaluronic acid with integrated 0.3% lidocaine. Clinically proven for 9-12 month duration, it features ultra-low endotoxin levels and exceptional 98.7% biocompatibility. KFDA-certified and manufactured under ISO 13485 standards, it demonstrates minimal swelling (1.2% incidence) in clinical trials.
- Enhanced Longevity: Maintains efficacy for 9-12 months with optimal tissue integration
- Pain Minimization: Integrated lidocaine reduces discomfort (VAS score ≤1.5)
- Safety Optimized: Hypoallergenic with endotoxin levels 60% below EU limits
- Precision Delivery: 27G ultra-fine needle enables superficial dermis injection
Cross-linked Hyaluronic Acid with Lidocaine HCl
Sterile single-use syringe with integrated needle
Controlled room temperature protected from light
24 months when stored properly
Contraindications: Pregnancy, active skin infections, hypersensitivity to components
Adverse Effects: Temporary swelling, redness, or bruising may occur
Professional Note: Strict aseptic technique required during administration
Warning: Not for self-administration or intravascular injection
• Bellast Ultra L requires prescription and professional administration
• Only for use by licensed medical practitioners
• Follow all local regulations for dermal filler procedures
• Monitor patients for hypersensitivity reactions
• Report any adverse events to local health authorities
We are an authorized wholesale distributor of medical aesthetic products. This product information is provided for professional healthcare providers only. We do not sell directly to end-users. All products must be administered by qualified medical professionals in accordance with local regulations. Product specifications may vary by batch – please confirm actual parameters before use. Product images may differ from actual packaging.
1 review for Bellast Ultra L Manufacturer+for sale
There are no reviews yet.